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Abstract
Background: The importance of toxicogenomics was recognized early in Korea and a group of
researchers was trying to build up a research infrastructure and educational system. However,
since the scale of the Korean pharmaceutical industry, which was expected to play the key role in
toxicogenomics was small compared to that of advanced countries, industry-sponsored large-scale
research projects and supporting infrastructures have been lacking in Korea.
Results: To improve this situation, the Korean government has exerted special efforts to promote
toxicogenomics research and development the last few years as an initiative to stimulate a
premature drug development industry on par with global competition and launched several large
scale research projects recently. Researchers are also trying to keep pace with government efforts
by organizing local scientist groups, training young toxicogenomics scientists, and widening the
toxicogenomic research efforts to environmental toxicity as well. Research and development from
bioinformatics and genomics venture companies are also contributing to uplifting the
competitiveness of the toxicogenomics industry.
Conclusion: Toxicogenomics in Korea is making steady progress in many directions. It is gaining
ground by government and related industries as well, the research is diversified to embrace
environmental genomics, and local research groups are making strategic links to international
research groups such as the MicroArray Quality Control (MAQC) consortium. We expect the
advancement of the Korean toxicogenomics research program will be beneficial not only to the
local society alone, but also to international scientists as a whole.
from First International Conference on Toxicogenomics Integrated with Environmental Sciences (TIES-2007)
Raleigh, NC, USA. 25–26 October 2007
Published: 10 March 2009
BMC Proceedings 2009, 3(Suppl 2):S6
<supplement> <title> <p>Proceedings of the First International Conference on Toxicogenomics Integrated with Environmental Sciences (TIES-2007)</p> </title> <editor>Pierre R Bushel (Senior Editor), Weida Tong and Dahlia Nielsen</editor> <note>Proceedings</note> <url>http://www.biomedcentral.com/content/pdf/1753-6561-3-S2-info.pdf</url> </supplement>
This article is available from: http://www.biomedcentral.com/1753-6561/3/S2/S6
© 2009 Chung et al; licensee BioMed Central Ltd. 
This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Proceedings 2009, 3(Suppl 2):S6 http://www.biomedcentral.com/1753-6561/3/S2/S6
Page 2 of 5
(page number not for citation purposes)
Background
The importance of toxicogenomics techniques in the accu-
rate prediction of the toxicity of chemicals under pre-clin-
ical evaluation is well-appreciated already.[1] In
particular, systems toxicology, which takes advantage of
the systems biological approaches, is presenting the possi-
bility of rapid and accurate toxicity prediction by integrat-
ing various "omics"-based techniques such as genomics,
transcriptomics, proteomics, metabolomics etc.[2] How-
ever, to take the full benefits of systems toxicology, there
are still issues to be resolved such as the standardization
and accumulation of different omics data and the promo-
tion of open access to various distributed data archives.[3]
Of course, the resolution of these issues demands concen-
trated efforts among researchers around the world. In
Korea as well, research efforts are expended from various
sides including government, academic organizations, and
industry, realizing the importance of toxicogenomics and
its down-stream effects. In this paper, we will briefly
review efforts to promote toxicogenomics in Korea by
focusing on the three sides iteratively.
Results
Government sector
The National Institute of Toxicological Research (NITR)
[4] is a leading government research agency in the field of
toxicogenomics in Korea. With a long-term mission to
develop toxicogenomics-based toxicity and safety assess-
ment techniques, NITR is conducting various research and
development projects. Among them is the construction of
s toxicoinformatics infrastructure called KOTIS, an acro-
nym of Korea Toxicoinformatics Integrated System, which
is carried out jointly with ISTECH Inc.[5]. KOTIS which is
modeled against ArrayTrack [6] and CEBS [7] is composed
of a database system and its analysis programs. It will
archive all government-funded toxicogenomics research
results in Korea and disseminate them back to interested
researchers (Figure 1). In particular, not only does it stores
and redistributes the basic experimental data but it also
allows users to download selected data needed for meta-
analysis after re-processing archived expression data on
top of quality assessment results. It will be able to deal
with most of the expression platforms currently used by
toxicogenomics researchers. Analysis programs are
designed to seamlessly work with the KOTIS database
under the client/server environment. The actual imple-
mentation focuses not only on conventional techniques
for expression data analysis such as quality assessment,
significant gene finding, clustering and classification, but
also on meta-analysis – a recent hot research issue in tox-
icogenomics. For meta-analysis, we will allow more
choices to users by implementing parametric and non-
parametric statistical techniques as well as the simple
"gene list agreement" method. This will allow users to
flexibly select an analysis method that is appropriate for
the characteristics of the data (Figure 2). KOTIS is
expected to level up the toxicogenomics research and
development in Korea tremendously. Besides the con-
struction of toxicoinformatic infrastructure, NITR is also
conducting various transcriptomics projects to accumu-
late data on toxicity-induced expression changes in
response to chemicals in model organisms by collaborat-
ing with academic researchers. NITR has already accumu-
lated expression profiles against ~100 toxic materials
through 22 independent projects in the year 2007. In
addition, NITR is also making great efforts to establish
international research cooperations with global research
organizations like the National Center for Toxicological
Research (NCTR).
The Korea Institute of Toxicology (KIT) [8] is another gov-
ernment agency that is operating a toxicogenomics special
team since year 2002. The toxicogenomics team is per-
forming researches on 5 specialized areas (genomic DNA
(SNP), RNA & gene expression, proteomics, cell culture
(siRNA), and histopathology & blood biochemistry) and
is specifically focusing on hepatotoxicity, nephrotoxicity,
and reproductive toxicology. Furthermore, by conducting
toxicogenomics research on the possibility of using mon-
key's peripheral blood mononuclear cells (PBMC) as a
surrogate tissue, it is expected to provide novel research
results on toxicogenomics which can be quite comple-
mentary to conventional ones that have been obtained
mostly in mice and rats.
Besides, the Korean Ministry of Environment recently
launched another large scale project aim at the utilization
of toxicogenomics techniques in evaluating environmen-
tal toxicity. It is expected that government-initiated toxi-
cogenomics research drives will be expanded
progressively.
Academic sector
Led by academic researchers, the establishment of "The
Korean Society of Toxicogenomics and Toxicoproteom-
ics"(KSTT) [9] in the year 2004 became the cornerstone
event for toxicogenomics in Korea. Its official journal
"Molecular and Cellular Toxicology"(MCT) has been the
central communication channel among local toxicoge-
nomics researchers since its inception and became a Sci-
ence Citation Index Expanded (SCIE) journal in just two
years. KSTT is making its best efforts to improve the con-
tents of MCT by inviting leading toxicogenomics scientists
to the editorial board and imposing stringent acceptance
criteria [10-12]. KSTT also places special emphasis on
opening global academic connections and addressing
local research results world wide by hosting international
workshops annually. Expanding the human resource
basis for toxicogenomics is an important mission of KSTT
and it is trying to educate the importance, and new devel-BMC Proceedings 2009, 3(Suppl 2):S6 http://www.biomedcentral.com/1753-6561/3/S2/S6
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opments of toxicogenomics to young researchers and
graduate-level students through numerous workshops
and topical schools. KSTT already gained 500+ regular
members in the year 2006. All these concerted efforts to
enhance public awareness for toxicogenomics eventually
culminated in launching the large scale project called
"Establishment and Application of Toxicogenomics for
Assessment and Prediction of Toxicity in Environmental
Aspects" by the Ministry of Environment. We expect the
proactive role played by KSTT will definitely be beneficial
in forming a solid foundation for toxicogenomics
research and development by expanding a professional
human resource basis, promoting public awareness and
support, and motivating communcations between
domestic and international researchers from the long-
term point of view.
Business sector
One particular aspect of the pharmaceutical industry in
Korea is that the scale of pharmaceutical companies is so
small that investment for a drug development infrastruc-
ture and related technology is almost negligible compared
to that of economically-developed countries. Therefore, it
is unimaginable to expect investments in toxicogenomics
research from local pharmaceutical industry. However,
this does not mean that there is no toxicogenomics
research activity from the business sector. Ironically, the
lack of investments in toxicogenomics from established
Architecture of KOTIS whole system Figure 1
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companies became a good opportunity for small genom-
ics and bioinformatics venture companies. They develop
toxicogenomics technologies and products such as toxic-
ity diagnosis chips through strategic alliances. One repre-
sentive example is the three-tiered alliance by Genocheck
[13] a genomics-oriented company, ISTECH a bioinfor-
matics company, and Shinwon Science [14] a pre-clinical
contract research organization (CRO). The alliance suc-
ceeded in developing the hepatotoxicity diagnosis chip
through the analysis of expression patterns of hepatotox-
icity molecules and the three companies are continuing
toxicogenomics research by applying information and
techniques acquired during the cooperation. Especially,
ISTECH is playing an important role in building up the
national toxicoinformatics infrastructure and developing
meta-analysis techniques through a joint research effort
with NITR.
Conclusion
Korean toxicogenomics is still in its infancy compared to
the US, EU or other advanced countries. However, govern-
ment-driven and well-designed investments are expected
to make critical contributions to toxicogenomics research
and development. Also, the establishment of KSTT and its
drive to research communication and education by aca-
demic scientists, and the continued research investment
and product development by venture companies are also
expected to promote domestic toxicogenomics research
and development.
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